華潤醫藥(03320.HK)旗下陽城漿站獲頒發單採血漿許可證
華潤醫藥(03320.HK)宣布,旗下華潤博雅生物控股子公司陽城漿站,獲得山西省衛生健康委員會頒發的《單採血漿許可證》(登記號:晉衛血字[2023]第001號)。該單採血漿站經核准登記,准予執業。
華潤醫藥指,血液製品領域兼具增長潛力與盈利能力、發展前景廣闊,是集團近年來重點關注的業務發展方向之一。同時,血液製品是國家戰略性儲備資源,關乎國家生物產業安全,加強血液製品行業整合、提升集中度是行業未來發展的重要趨勢。華潤博雅生物為華潤醫藥的血液製品業務平台,是次陽城漿站獲得《單採血漿許可證》將有利於進一步提升華潤博雅生物原料血漿的供應能力,增厚公司業績,亦有助於華潤醫藥進一步做強做大血液製品業務,提升整體綜合競爭力和市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.